Despite advances in diagnostic imaging, the evolution of neoadjuvant chemotherapy and the refinements in limb-salvage surgery, the progression-free survival rate remains poor for patients with metastatic, recurrent or unresectable osteosaroma. Different therapeutic strategies for these subgroups of patients have been employed to control disease and prolong survival. Treatment options are limited and controversial, including systemic and localized therapies. Surgical resection, whenever feasible, is still the standard treatment in advanced osteosarcoma. The role of chemotherapy is unclear while the use of radiotherapy, embolization and thermal ablation is increasing. New therapeutic experimental approaches and novel target therapies are needed to improve the outcome of these subgroups of patients.

Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, et al. (2011). Palliative therapy for osteosarcoma. EXPERT REVIEW OF ANTICANCER THERAPY, 11(2), 217-227 [10.1586/ERA.10.172].

Palliative therapy for osteosarcoma.

RUGGIERI, PIETRO;PICCI, PIERO;BACCI, GAETANO;MERCURI, MARIO
2011

Abstract

Despite advances in diagnostic imaging, the evolution of neoadjuvant chemotherapy and the refinements in limb-salvage surgery, the progression-free survival rate remains poor for patients with metastatic, recurrent or unresectable osteosaroma. Different therapeutic strategies for these subgroups of patients have been employed to control disease and prolong survival. Treatment options are limited and controversial, including systemic and localized therapies. Surgical resection, whenever feasible, is still the standard treatment in advanced osteosarcoma. The role of chemotherapy is unclear while the use of radiotherapy, embolization and thermal ablation is increasing. New therapeutic experimental approaches and novel target therapies are needed to improve the outcome of these subgroups of patients.
2011
Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, et al. (2011). Palliative therapy for osteosarcoma. EXPERT REVIEW OF ANTICANCER THERAPY, 11(2), 217-227 [10.1586/ERA.10.172].
Errani C; Longhi A; Rossi G; Rimondi E; Biazzo A; Toscano A; Alì N; Ruggieri P; Alberghini M; Picci P; Bacci G; Mercuri M.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/101919
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 68
  • ???jsp.display-item.citation.isi??? 56
social impact